scheduled to initiate treatment per the recommendations of their primary oncologist, will
receive a single dose of vincristine 2 milligrams (mg). The objective is to determine if
this single dose will induce rapid cell death in isolated CLL cells.
Vincristine 2 mg will be administered to the participants intravenously over 5 minutes.
Blood samples will be collected from an intravenous line inserted into the contralateral
limb to that where the vincristine was given, at time zero (pre-vincristine treatment),
immediately after vincristine administration (within 2-10 minutes upon completion of
administration) and at 1, 2, 4 and 6 hours post-vincristine treatment. Patients will then
at a later date receive chemotherapy treatment as prescribed by their primary oncologist.
Within 7 days of vincristine administration, participants will receive a phone call from the
research nurse to discuss potential toxicities. At the time of the initiation of standard
chemotherapy treatment, the Principal Investigator will also meet with the participant to
collect information regarding adverse events.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: firstname.lastname@example.org
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.